NO970312L - Karbonmonoksidavhengige guanylylcyklase modifiseringsmidler - Google Patents

Karbonmonoksidavhengige guanylylcyklase modifiseringsmidler

Info

Publication number
NO970312L
NO970312L NO970312A NO970312A NO970312L NO 970312 L NO970312 L NO 970312L NO 970312 A NO970312 A NO 970312A NO 970312 A NO970312 A NO 970312A NO 970312 L NO970312 L NO 970312L
Authority
NO
Norway
Prior art keywords
naturally occurring
cellular
carbon monoxide
guanylyl cyclase
variety
Prior art date
Application number
NO970312A
Other languages
English (en)
Other versions
NO970312D0 (no
Inventor
Alvin J Galsky
Michel P Rathbone
Original Assignee
Alvin J Galsky
Michel P Rathbone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/280,719 external-priority patent/US5447939A/en
Priority claimed from US08/488,976 external-priority patent/US5801184A/en
Application filed by Alvin J Galsky, Michel P Rathbone filed Critical Alvin J Galsky
Publication of NO970312D0 publication Critical patent/NO970312D0/no
Publication of NO970312L publication Critical patent/NO970312L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Det beskrives firemgatigsmåter og dertil horende blandinger og medikamenter generelt vedrørende kontroll av cellulær og neural aktivitet og for selektivt og kontrollerbart å fjremkalle in vivo genetisk ekspresjon av ett eller flere naturlig forekommende genetisk kodede molekyler i pattedyr. Nærmere bestemt vil den foreliggende oppfmnelse selektivt aktivere eller derepressere gener som koder for spesifikke naturlig forekom- mende molekyler såsom proteiner eller neurotrofe faktorer og forårsake endogen fremstilling av sILke naturlig forekommende forbindelser ved admini- strering av karbonmonoksidavhengige guanylyl- cyklasemodulerende purinderivater. Fremgangsmåt- ene LEialge den foreliggende oppfnmelse kan anven- des til å påvirke flere forskjellige celltilære og neu- rologiskc fbnksjonec og aktiviteter og til terapeutisk eller profylaktisk behandling av en rekke forskjel- lige neurodegcnerative, neurologiskc, cellulære og fysiologiske forstyrrelser.
NO970312A 1994-07-25 1997-01-24 Karbonmonoksidavhengige guanylylcyklase modifiseringsmidler NO970312L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/280,719 US5447939A (en) 1994-07-25 1994-07-25 Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US08/488,976 US5801184A (en) 1994-07-25 1995-06-08 Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US49292995A 1995-07-20 1995-07-20
PCT/US1995/010008 WO1996003125A1 (en) 1994-07-25 1995-07-25 Carbon monoxide dependent guanylyl cyclase modifiers

Publications (2)

Publication Number Publication Date
NO970312D0 NO970312D0 (no) 1997-01-24
NO970312L true NO970312L (no) 1997-01-27

Family

ID=27403169

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970312A NO970312L (no) 1994-07-25 1997-01-24 Karbonmonoksidavhengige guanylylcyklase modifiseringsmidler

Country Status (13)

Country Link
US (3) US6350752B1 (no)
EP (1) EP0772440A4 (no)
JP (1) JPH10504814A (no)
AU (1) AU709454B2 (no)
BR (1) BR9508339A (no)
CA (1) CA2195302A1 (no)
CZ (1) CZ380296A3 (no)
FI (1) FI970302A0 (no)
HU (1) HUT76294A (no)
NO (1) NO970312L (no)
NZ (1) NZ291592A (no)
PL (1) PL318293A1 (no)
WO (1) WO1996003125A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338963B1 (en) * 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
EP1790344B1 (en) 2000-07-07 2011-02-23 Spectrum Pharmaceuticals, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
FR2814077A1 (fr) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2042181A1 (en) * 2002-02-04 2009-04-01 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CN100436468C (zh) * 2005-06-24 2008-11-26 中国医学科学院基础医学研究所 一类嘌呤核苷酸化合物、其药物组合物及其制药用途
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US20120058099A1 (en) * 2009-03-04 2012-03-08 Children's Medical Center Corporation Use of hypoxanthine for promotion of neuronal outgrowth
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321369A (en) 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3484521A (en) 1966-06-23 1969-12-16 Int Chem & Nuclear Corp Enhancement of memory processes in mammals with basic addition salts of ribonucleic acid
DE2554453A1 (de) * 1974-12-18 1976-06-24 Experimentales Et Cliniques De Medikament zur glykaemieregulierung
US4221909A (en) 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4221910A (en) 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
US4221794A (en) 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4728605A (en) 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
US4952693A (en) 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives
US5256677A (en) * 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5091432A (en) * 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
EP1790344B1 (en) * 2000-07-07 2011-02-23 Spectrum Pharmaceuticals, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions

Also Published As

Publication number Publication date
PL318293A1 (en) 1997-06-09
FI970302A7 (fi) 1997-01-24
FI970302L (fi) 1997-01-24
WO1996003125A1 (en) 1996-02-08
CA2195302A1 (en) 1996-02-08
EP0772440A1 (en) 1997-05-14
AU3277595A (en) 1996-02-22
US20020165242A1 (en) 2002-11-07
NO970312D0 (no) 1997-01-24
HU9603591D0 (en) 1997-02-28
NZ291592A (en) 2001-03-30
JPH10504814A (ja) 1998-05-12
BR9508339A (pt) 1997-09-30
FI970302A0 (fi) 1997-01-24
EP0772440A4 (en) 1999-05-19
AU709454B2 (en) 1999-08-26
HUT76294A (en) 1997-07-28
US20060063788A1 (en) 2006-03-23
CZ380296A3 (cs) 1998-01-14
US6350752B1 (en) 2002-02-26

Similar Documents

Publication Publication Date Title
NO970312L (no) Karbonmonoksidavhengige guanylylcyklase modifiseringsmidler
Piñeiro et al. Fifteen years of prothymosin alpha: contradictory past and new horizons
MISHIMA et al. Induction of melanogenesis suppression: cellular pharmacology and mode of differential action
IL121790A0 (en) Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (GDNF) protein product
AU3368497A (en) Human dnase i hyperactive variants
PL322015A1 (en) Derivatives of hydroxylamine useful as compounds enhancing production of accompanying molecular protein and ethod of obtaining them
AU2155795A (en) Alphavirus cdna vectors
DE69737740D1 (de) GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
CA2223433A1 (en) Ob protein compositions and methods
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
BG102733A (en) New substituted cyclic amino acids as pharmaceutical forms
PT917571E (pt) Gene relacionado com agouti
ATE280833T1 (de) Kationische lipide/dns komplexe zum zielen von genen
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
NZ314839A (en) 1,25-Dihydroxy-16,23Z-diene-20-epi-16-ene-cholecalciferol (Vitamin D3) analogues
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
NO20021829L (no) Anvendelse av karbonmonoksyd-avhengige guanylylcyklase- modifisatorer for å stimulere neuritogenese
WO1998020029A3 (en) Hnf3-delta compositions
Ali et al. A Comparative, Randomized, Double-Blinded, and Vehicle-Controlled Study for the Reduction in Facial Pigmentation after Treatment with both Tranexamic Acid and Tranexamic Acid Ethyl Ester.
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
EP0770137A4 (en) IMPROVEMENTS IN PROTEIN PRODUCTION IN HOST CELLS
WO2001044443A3 (en) Cytochrome p450rai-2 and related proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application